- Home
- CSTL vs GPRK Comparison
CSTL vs GPRK Comparison
Compare CSTL & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSTL | GPRK |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 649.0M |
| IPO Year | 2019 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CSTL | GPRK |
|---|---|---|
| Price | $28.00 | $9.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $45.50 | $8.50 |
| AVG Volume (30 Days) | 290.0K | ★ 357.8K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | $39.45 |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | ★ N/A | $12.70 |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $5.75 |
| 52 Week High | $44.28 | $11.87 |
Technical Indicators
Market Signals| Indicator | CSTL | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 75.45 | 48.57 |
| Support Level | $22.67 | $9.47 |
| Resistance Level | $34.97 | $10.26 |
| Average True Range (ATR) | 1.31 | 0.35 |
| MACD | 0.33 | -0.03 |
| Stochastic Oscillator | 84.88 | 37.89 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
About GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.